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SUMMARY – The objective of our research was to compare the results of human papillomavirus 
(HPV) typing and occurrence of the most important risk factors for cervical cancer obtained in the 
towns of northern, central and southern regions of Montenegro, in subjects between 30 and 35 years 
of age, in accordance with the new screening program introduced by the Ministry of Health of Mon-
tenegro in 2018. The study included 400 patients aged 30-35 years from Rožaje, Berane, Budva and 
Podgorica, 100 from each town, who underwent HPV typing in accordance with the latest screening 
program for early detection and prevention of cervical cancer, approved by the Ministry of Health of 
Montenegro in 2018. The material was obtained and sampled at the Health Clinics in Rožaje, Berane, 
Podgorica and Budva. Specially designed brushes were used to take swabs from the cervices, which 
were then sampled in separate collection tubes that contained a liquid transport medium. The samples 
were then sent for further analysis to the Institute of Public Health of Montenegro where HPV typ-
ing was performed using the real-time polymerase chain reaction method. The results were encrypted 
and obtained electronically. The data obtained from the questionnaires each subject filled out in ac-
cordance with this program were analyzed and the subjects willingly agreed to partake in the screening 
program. Nearly one-quarter of subjects had a positive HPV finding. The group of HPV positive 
women included significantly more women from Podgorica (χ2-test=26.455, p<0.001), women with 
very good living conditions (χ2-test=12.264, p<0.001), women who smoked cigarettes (χ2-test=5.074, 
p=0.024), women who had the first sexual intercourse between the ages of 17 and 20 (χ2-test=5.874, 
p=0.015), and women who did not have permanent partners (χ2-test=6.061, p=0.014). Among the 
observed socio-demographic characteristics and sexual behaviors of our subjects that proved to be 
non-significant variables in their HPV statuses we excluded the length of smoking habit (χ2-test=0.638, 
p=0.424) and protected sexual intercourse (χ2-test=2.628, p=0.105). By implementing the screening 
program and HPV typing, we came to a conclusion that the problem of cervical cancer could be solved 
or at least mitigated by raising awareness of the causes and incidence of cervical cancer, as well as by 
being well informed on its curability, predictability and protection during intercourse, which would 
contribute to positive changes.
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Introduction
Systemized examinations have led to a decrease in 
cervical cancer mortality in the last fifty years. How-
Azra Lukač et al. Cervical cancer prevention via HPV screening in Montenegro
Acta Clin Croat, Vol. 59, No. 2, 2020 295
ever, many developing countries, including Montene-
gro, have not benefited much from the examination 
program, and in some developed countries there has 
been an increase of cervical cancer occurrence. Human 
papillomavirus (HPV) has been recognized as the pri-
mary cause of the disease and significant coexistent 
factors have also been identified. These are crucial steps 
towards developing effective programs for the preven-
tion and successful treatment of cervical cancer, which 
can be adapted to different countries. It is important to 
note that in Montenegro, cervical cancer affects about 
100 women annually, 30-40 of which die1,2. Given that 
Montenegro is a country with about 630,000 inhabit-
ants, such data along with the fact that cervical cancer 
is the second most common disease in women in 
Montenegro, right after breast cancer, are worrying. 
Cervical cancer in developing countries is so frequent 
due to the inaccessibility of screening tests that would 
identify or predict this type of cancer (HPV testing, 
etc.) and enable treatment or prevention. It is estimat-
ed that approximately 5% of women in developing 
countries undergo tests for cervical cancer, whereas in 
developed countries over 40% of women are regularly 
tested3. In 99% of cases, women with cervical cancer 
tested positive for HPV DNA and cervical dysplasia 
related to it, indicating not only that is HPV one of the 
main causes of cervical cancer, but that this type of 
cancer can be detected on time.
Unfortunately, in most developing countries, the ap-
proach to cervical cancer treatment is very aggressive, 
usually through performing complicated and risky sur-
geries or hysterectomy, which leads to numerous side 
effects and complications. Ambulatory surgeries, such as 
cryotherapy, laser surgery and the like, are most effective, 
but, unfortunately, there is little probability of imple-
menting them in developing countries.
Since January 2018, a new screening program for 
early detection and prevention of cervical cancer in 
Montenegro has created conditions for HPV DNA 
test, which is now conducted in all towns covering pa-
tients born between 1983 and 1988.
The objective of our research was to obtain the re-
sults of HPV typing. We analyzed the incidence of the 
most important risk factors for cervical cancer and 
their correlation with HPV infection in female pa-
tients between the ages of 30 and 35, in the towns of 
northern, central and southern regions of Montenegro, 
in accordance with the first screening program for the 
prevention and early detection of cervical cancer ever 
conducted in Montenegro, that was also approved by 
the Ministry of Health of Montenegro.
Materials and Methods
This prospective study was conducted in the towns 
of northern, central and southern regions of Montene-
gro. The study lasted from January 2018 until January 
2019 and included a planned population of 400 female 
subjects (100 subjects from the towns of Berane, 
Rožaje, Budva and Podgorica), born between 1983 and 
1988, selected by the Health Insurance Fund of Mon-
tenegro in accordance with the regulations of screen-
ing program for the prevention and early detection of 
cervical cancer approved by the Ministry of Health of 
Montenegro. The material was obtained and sampled 
at the Health Clinics in Rožaje, Berane, Podgorica and 
Budva. Specially designed brushes were used to take 
swabs from the cervices, which were then sampled in 
separate collection tubes that contained a liquid trans-
port medium. The samples were then sent for further 
analysis to the Institute of Public Health of Montene-
gro where HPV typing was performed, using the real- 
-time polymerase chain reaction (PCR) method. The 
results were encrypted and obtained electronically. The 
data obtained from the questionnaires each subject 
filled out in accordance with this program were ana-
lyzed and the subjects willingly agreed to partake in 
the screening program.
Statistical analysis
For the analysis of primary data, we used descrip-
tive statistical methods and statistical hypothesis test-
ing. We used relative numbers as the descriptive statis-
tical method. The χ2-test was used to analyze differ-
ences between frequency values. Statistical hypotheses 
were tested at the level of statistical significance of 
0.05. For the purpose of statistical data analysis, SPSS 
Statistics 22 software package was used.
Results
Positive HPV findings were recorded in 122 sub-
jects (28% of the total study population), whereas 288 
(72%) subjects had negative results. As regards the 
socio-demographic characteristics and sexual behavior 
of the subjects, we considered the place of residence 
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(χ2-test=42.956, p<0.001), living conditions (χ2-test= 
19.006, p<0.001), smoking habit (χ2-test=5.074, p= 
0.024), first sexual intercourse (χ2-test=15,159, p= 
0.002), and having a permanent partner (χ2-test=6.061, 
p=0.014) as significant variables affecting the HPV 
status.
In the group of women who were HPV positive, 
there were significantly more women from Podgorica 
(χ2-test=26.455, p<0.001), women with very good liv-
ing conditions (χ2-test=12.264, p<0.001), women who 
smoked cigarettes (χ2-test=5.074, p=0.024), women 
who had their first sexual intercourse between the ages 
of 17 and 20 (χ2-test=5.874, p=0.015), and women 
without permanent partners (χ2-test=6.061, p=0.014).
As regards the socio-demographic characteristics 
and sexual behavior of the subjects, we found that the 
length of smoking habit (χ2-test=0.638, p=0.424) and 
protected sexual intercourse (χ2-test=2.628, p=0.105) 
were not significant variables affecting the HPV status.
The gynecologic characteristics and associated dis-
eases that significantly affected the HPV status were 
the presence of anemia (χ2-test=8.974, p=0.003), num-
ber of childbirths (χ2-test=13.537, p=0.004), menarche 
(t=2.283, p=0.023), abortion (χ2-test=8.921, p=0.003), 
and usage of intrauterine devices (IUDs) (χ2-test= 
6.772, p=0.009).
In the group of women who were HPV positive, 
there were significantly more women with anemia (χ2-
test=8.974, p=0.003), nulliparous women (χ2-test= 
9.902, p=0.002), women with early menarche (t=2.283, 
p=0.023), women who did not have abortions (χ2-
test=8.921, p=0.003) and women who never used 
IUDs (χ2-test=6.772, p=0.009).
The gynecologic characteristics and associated dis-
eases that did not have a statistically significant effect 
on the HPV status were systemic diseases (χ2-test= 
0.087, p=0.768), impaired immunity and previous 
treatment of systemic diseases (χ2-test=2.824, p=0.093), 
malignant gynecologic diseases in close relatives (χ2-
test=3.018, p=0.082), age of the affected relative (p= 
0.653), usage of oral contraceptives (χ2-test=1.235, 
p=0.266), and current usage of IUDs (χ2-test=1.924, 
p=0.165).
The results of univariate logistic regression model 
analysis showed that the variables associated with an 
increased risk of HPV infection were the place of resi-
dence [central region (B=1.13, p=0.002) compared to 
the northern region taken as a reference category] and 
anemia (B=1.91, p=0.012), while menarche (B=-0.22, 
p=0.017) and abortion (B=-0.69, p=0.043) had re-
duced the risk of HPV infection.
The multivariate logistic regression model included 
4 predictors and the entire model was statistically sig-
nificant (χ2-test=54.856, p<0.001). According to the 
multivariate logistic regression model, the statistically 
significant predictors associated with an increased risk 
of HPV infection were the place of residence [central 
Table 1. Socio-demographic characteristics and sexual 





n (%) n (%)
288 (72.0) 112 (28.0)
Residence
Northern region 168 (58.3) 32 (28.6)
<0.001*Central region 52 (18.1) 48 (42.9)
Southern region 68 (23.6) 32 (28.6)
Living conditions
Good 136 (47.2) 29 (25.9)
<0.001*Very good 51 (17.7) 38 (33.9)
Excellent 101 (35.1) 45 (40.2)
Smoker
No 82 (63.2) 57 (50.9)
0.024*
Yes 106 (36.8) 55 (49.1)
Length of smoking 
habit
<10 years 71 (66.4) 33 (60.0)
0.424
>10 years 36 (33.6) 22 (40.0)
Age at first sexual 
intercourse (years)
<16 20 (6.9) 15 (13.4)
0.002*
17-20 136 (47.2) 68 (60.7)
21-24 100 (34.7) 24 (21.4)
>25 32 (11.1) 5 (4.5)
Permanent partner
No 42 (14.6) 28 (25.0)
0.014*
Yes 246 (85.4) 84 (75.0)
Protected sexual 
intercourse
No 251 (87.2) 104 (92.9)
0.105
Yes 37 (12.8) 8 (7.1)
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Table 2. Distribution of gynecologic characteristics and associated diseases that affect the 




n (%) n (%)
288 (72.0) 112 (28.0)
Systemic diseases
No 277 (96.2) 107 (95.5)
0.768
Yes 11 (3.8) 5 (4.5)
Impaired immunity and current 
treatment of systemic diseases
No 273 (94.8) 101 (90.2)
0.093
Yes 15 (5.2) 11 (9.8)
Anemia
No 285 (99.0) 105 (93.8)
0.003*
Yes 3 (1.0) 7 (6.3)
Malignant gynecologic diseases  
in close relatives 
No 277 (96.2) 103 (92.0)
0.082
Yes 11 (3.8) 9 (8.0)
Age of the affected relative (years)
30-40 4 (36.4) 5 (55.6)
0.653
41-50 7 (63.6) 4 (44.4)
Age at first menarche (years)  
(mean ± standard deviation) 13.3±1.5 13.0±1.4 0.023*
Number of childbirths
0 53 (18.4) 37 (33.0)
0.004*
1 58 (20.1) 25 (22.3)
2 90 (31.3) 31 (27.7)
≥3 87 (30.2) 19 (17.0)
Abortions
No 212 (73.6) 98 (87.5)
0.003*
Yes 76 (26.4) 14 (12.5)
Oral contraceptives
No 283 (98.3) 108 (96.4)
0.266
Yes 5 (1.7) 4 (3.6)
Are you using an IUD
No 275 (95.5) 103 (92.0)
0.165
Yes 13 (4.5) 9 (8.0)
Have you ever used an IUD
No 266 (92.4) 111 (99.1)
0.009*
Yes 22 (7.6) 1 (0.9)
IUD = intrauterine device
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region (B=1.59; p<0.001) and southern region (B=0.69, 
p=0.021) compared to the northern region taken as a 
reference category] and anemia (B=1.98, p=0.012), 
while menarche (B=-0.22; p=0.010) and abortion (B=-
0.79; p=0.018) were associated with reduction in the 
risk of HPV infection.
Discussion
Just over a quarter of subjects had a positive HPV 
finding. Positive HPV genotypes 33, 35, 39 were sta-
tistically significantly more frequent in Podgorica 
compared to other places of residence (χ2-test=26.455, 
p<0.001), in women with very good living conditions 
(χ2-test=12.264, p<0.001), in women who smoked cig-
arettes (χ2-test=5.074, p=0.024), in women who had 
their first sexual intercourse between the ages of 17 
and 20 (χ2-test=5.874, p=0.015), and in women with-
out permanent partners (χ2-test=6.061, p=0.014).
Diagnostic screening for HPV lesions is generally 
available in the developed world but scarce everywhere 
else for the lack of public health policy, professional and 
general education, media awareness, clinical settings, fi-
nancial resources and, most crucially, insufficient capac-
ity for effective follow-up treatment of identified le-
sions. Screening is typically visual and subjective, with 
which even the most highly trained experts sometimes 
are unable to agree. New tests for molecular biomarkers 
Table 3. Logistic regression with human papillomavirus (HPV) status as a dependent variable
Independent variable
Univariate Multivariate
B p OR (95%CI) B p OR (95%CI)
Residence
Northern region Reference category
Central region 1.13 0.002 3.1 (1.5-6.3) 1.59 <0.001 4.9 (2.8-8.6)
Southern region 0.46 0.214 1.6 (0.8-3.2) 0.69 0.021 2.0 (1.1-3.6)
Living conditions
Good Reference category
Very good 0.59 0.111 1.8 (0.9-3.7)
Excellent 0.13 0.713 1.1 (0.6-2.2)
Smoker 0.25 0.321 1.3 (0.8-2.1)
Age at first sexual 
intercourse (years)
<16 Reference category
16-20 -0.09 0.819 0.9 (0.4-2.0)
21-24 -0.49 0.276 0.6 (0.3-1.5)
>25 -1.01 0.108 0.4 (0.1-1.2)
With permanent partner -1.97 0.921 1.0 (0.5-1.8)
Anemia 1.91 0.012 6.7 (1.5-29.9) 1.98 0.009 7.3 (1.6-32.0)
First menarche -0.22 0.017 0.8 (0.7-1.0) -0.22 0.010 0.8 (0.7-0.9)
Number of childbirths
0 Reference category
1 -0.23 0.508 0.8 (0.4-1.6)
2 -0.10 0.781 0.9 (0.5-1.8)
≥3 -0.13 0.756 0.9 (0.4-1.9)
Abortion -0.69 0.043 0.5 (0.3-1.0) -0.79 0.018 0.5 (0.2-0.9)
IUDs used in the past 0.13 0.184 0.2 (0.03-2.0)
IUD = intrauterine device
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of infection and disease have greatly improved the sen-
sitivity and reliability, and are beginning to help define 
the degree of present and future risk4.
About 80% of cases of cervical cancer occur in de-
veloping countries, mainly in Central America, Africa 
south of the Sahara and Melanesia5. In these regions, 
cervical cancer is one of the leading causes of death in 
women and causes around 190,000 deaths a year6.
As regards the socio-demographic characteristics 
and sexual behavior of subjects, we determined that 
the length of smoking habit (χ2-test=0.638, p=0.424) 
and protected sexual intercourse (χ2-test=2.628, p= 
0.105) were not significant variables affecting the 
HPV status.
Tobacco use is also a known risk factor for cervical 
cancer7. Direct carcinogenic effect of cigarette smok-
ing on the cervix is supported by the fact that nicotine 
metabolites can be found in cervical mucus of women 
smokers8. Women who smoke 15 and more cigarettes 
a day are at twice as high risk of HPV infection com-
pared to non-smokers. The risk is at its highest in 
women between the ages of 45 and 50, while about 
37% of women developing HPV infection are under 
the age of 35. Women older than 65 make up 10% of 
patients9-11.
Patients with HPV-positive oropharyngeal carci-
noma (OPC) had higher income and education level 
than patients with HPV-negative OPC, and among 
patients with HPV-positive OPC, never/light smokers 
had the highest income and education levels. Sexual 
exposures were more common among patients with 
HPV-positive tumors, particularly smokers with 
HPV-positive tumors, and sexual exposures were more 
common among patients with higher education level 
and socioeconomic status12.
The gynecologic characteristics and associated dis-
eases that did not significantly affect the HPV status 
according to our study were systemic diseases (χ2-test= 
0.087, p=0.768), impaired immunity and current treat-
ment of systemic diseases (χ2-test=2.824, p=0.093), ma-
lignant gynecologic diseases in close relatives (χ2-test= 
3.018, p=0.082), age of the affected relative (p=0.653), 
use of oral contraceptives (χ2-test=1.235, p=0.266), and 
current usage of IUDs (χ2-test=1.924, p=0.165).
Generally, there is a high prevalence of HPV infec-
tion in younger population throughout Europe13, in-
cluding our country, which can heavily be influenced by 
early initiation of sexual intercourse among young peo-
ple of European countries (over 78% of them have their 
first sexual intercourse before the age of 18)9,14. In the 
last thirty years, epidemiological studies have shown 
that sexual behavior has an impact on the risk of cervical 
cancer, e.g., number of partners, age at first sexual inter-
course and partner’s sexual behavior15,16.
The gynecologic characteristics and associated dis-
eases that significantly affected the HPV status were 
the presence of anemia (χ2-test=8.974, p=0.003), num-
ber of childbirths (χ2-test=13.537, p=0.004), menarche 
(t=2.283, p=0.023), abortion (χ2-test=8.921, p=0.003), 
and usage of IUDs (χ2-test=6.772, p=0.009).
In the group of women who were HPV positive, 
significantly more frequent were women with anemia 
(χ2-test=8.974, p=0.003), nulliparous women (χ2-test= 
9.902, p=0.002), women with early menarche (t=2.283, 
p=0.023), women who did not have abortions (χ2-
test=8.921, p=0.003), and women who never used 
IUDs (χ2-test=6.772, p=0.009).
Systemic diseases and immune system impairment 
certainly contribute to the development of cervical 
cancer, particularly if it is combined with one or more 
cofactors, e.g., viral infection or bacterial vaginosis. 
Studies have shown that bacterial vaginosis is statisti-
cally significantly more frequent in subjects with cervi-
cal precancerous lesions or cervical cancer than in 
healthy women17.
Patients suffering from chronic infections or in-
flammatory diseases usually develop normocytic nor-
mochromic anemia, followed by characteristic hypo-
ferremia. This usually moderate anemia is caused by a 
reduced production of red blood cells (RBC) in com-
bination with a slight decrease in RBC life span18. 
Based on the interaction among iron, immunity and 
infection, anemia is considered to have a highly unde-
sirable effect. The RBC production has evolved to be-
come very sensitive to reduced iron availability, regard-
less of whether it is a real iron deficiency or an inflam-
matory iron restriction. The inhibition of erythropoie-
sis by hypoferremia preserves iron for other metabolic 
uses during infection, and can facilitate diversion of 
bone marrow protectors towards the production of 
leukocytes for host defense. Experimental evidence 
suggests that erythropoiesis is uniquely sensitive to hy-
poferremia19 and that other tissues can use iron even 
when it is available at much lower concentrations than 
normal. Because of the relatively long RBC life span (4 
months), it takes several weeks for anemia to develop, 
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unless there is a significantly increased RBC destruc-
tion or blood loss, which can be seen in rapidly evolv-
ing anemia accompanying infectious diseases. Hypo-
ferremia is not the only consequence of inflammation 
that limits erythropoiesis. Inflammatory cytokines di-
rectly suppress erythropoiesis, likely to increase the 
production of leukocytes, and also activate macro-
phages for increased erythrophagocytosis20.
It has been proven that female partners of patients 
that developed cancer on one of the reproductive organs 
have an increased risk of developing cervical cancer21.
The age of the relatives who were cancer patients 
had no statistical significance since the frequency was 
very low.
The number of successful deliveries is also a very 
important factor in developing countries, where ex-
aminations are not readily available. It is considered 
that the higher the number of childbirths, the higher is 
the risk of cervical cancer. Research that supports this 
claim was carried out in Central and South America22.
We should also point out the significance of the 
vaccines produced to fight and reduce the incidence of 
cervical cancer. Two vaccines that prevent infection 
with HPV types 16 and 18 have been approved by the 
European Medicines Agency but, in our country, they 
are applied selectively, so there are no statistical data 
on their usage. Successful Pap tests have reduced the 
incidence of cervical cancer in developed countries by 
50%23. During 2017, the Institute of Public Health in 
coordination with the Departments of Gynecology 
and Pediatrics established a Working Group that 
strives towards the adoption of the Act on Compul-
sory HPV Vaccination of children aged 9 to 14, the 
implementation of which is planned to be finished by 
the end of 2019.
There is high‐reliable evidence that HPV vaccines 
protect against cervical pre-cancer in adolescent girls 
and women who are vaccinated between 15 and 26 years 
of age. The protection is lower when a part of the popu-
lation is already infected with HPV. Longer follow‐up 
is needed to assess the impact on cervical cancer. The 
vaccines do not increase the risk of serious adverse 
events, miscarriage or pregnancy termination. There are 
limited data from trials on the effect of vaccines on 
deaths, stillbirth and babies born with malformations24.
Clarification of the molecular mechanism underly-
ing HPV persistence and related cervical cancer will 
help predict the prognosis of patients with HPV infec-
tions at an earlier stage. Molecular classification based 
on HPV integration and genetic profiling may also 
translate into the precision medicine that allows clini-
cians to focus medical resources more on high‐risk pa-
tients whose diseases are genuinely progressing, greatly 
reducing the psychological and economic burdens of 
the cervical screening programs and HPV vaccination 
programs in the future25.
Conclusion
By implementing the screening program and HPV 
typing, we came to the conclusion that the problem of 
cervical cancer could be solved or at least mitigated by 
raising awareness of the causes and incidence of cervi-
cal cancer, as well as by being well informed on its cur-
ability, predictability and protection during inter-
course, which would contribute to positive changes.
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Sažetak
HPV TIPIZACIJA KAO PROGRAM PROBIRA ZA PREVENCIJU I RANO OTKRIVANJE  
RAKA GRLIĆA MATERNICE U RAZLIČITIM CRNOGORSKIM REGIJAMA
A. Lukač, N. Šulović, S. Smiljić, A. N. Ilić i M. Šašić
Cilj našega istraživanja bio je usporediti rezultate tipizacije humanog papilomavirusa (HPV) i zastupljenosti najvažnijih 
čimbenika rizika za oboljele od raka grlića maternice između gradova sjevernog, centralnog i južnog područja Crne Gore u 
populaciji žena u dobi od 30-35 godina, predviđene novim programom probira koji je Ministarstvo zdravlja Crne Gore uve-
lo 2018. godine. Studijom su obuhvaćene bolesnice iz Rožaja, Berana, Budve i Podgorice, ukupno njih 400 (po 100 iz svakog 
grada) kod kojih je provedena HPV tipizacija predviđena najnovijim programom probira za rano otkrivanje i prevenciju raka 
grlića maternice Ministarstva zdravlja Crne Gore u 2018. godini. Materijal je uzorkovan u ambulantama Domova zdravlja u 
Rožajama, Beranama, Podgorici i Budvi. Specijalnim četkicama se uzima bris s grlića maternice, a zatim uzorkuje u posebnoj 
epruveti s podlogom i šalje na analizu u Institut za javno zdravlje Crne Gore gdje se radi HPV tipizacija metodom RT-PCR 
(real-time polymerase chain reaction). Rezultati su se dobivali elektronički i šifrirani. Svim ispitanicama su se uzeli i analizirali 
podaci iz anketnog upitnika koji je sastavljen kao dio ovoga programa, a ispitanice su dobrovoljno pristale na program pro-
bira. Gotovo jedna četvrtina ispitanica je imala pozitivan nalaz HPV. U skupini žena pozitivnih na HPV bilo je značajno više 
žena iz Podgorice (χ2-test=26,455, p<0,001), žena koje imaju vrlo dobre uvjete života (χ2-test=12,264, p<0,001), žena koje 
puše cigarete (χ2-test=5,074, p=0,024), žena koje su imale prvi seksualni odnos u dobi od 17-20 godina (χ2-test=5,874, 
p=0,015) i žena koje nemaju stalne partnere (χ2-test=6,061, p=0,014). Promatrajući sociodemografske karakteristike i seksu-
alno ponašanje ispitanica prema HPV statusu kao varijable koje nisu pokazale značajnost izdvojile su se pušački staž (χ2-
test=0,638, p=0,424) i žaštićen seksualni odnos (χ2-test=2,628, p=0,105). Provođenjem programa probira i HPV tipizacije 
dolazimo do zaključka da bi se problem mogao riješiti ili barem ublažiti podizanjem svijesti o uzrocima i učestalosti raka 
grlića maternice kao i informiranosti o izlječivosti, predvidljivosti i seksualnoj zaštiti, što bi doprinijelo pozitivnim promje-
nama.
Ključne riječi: HPV infekcija; Čimbenici rizika; Karcinom grlića maternice
